Pumping, Plugging, and Protecting: The Hidden Logic of Resistance

As discussed in the prior post, antibiotic resistance remains one of the most fascinating and consequential topics in Infectious Diseases. In Part I, the focus was on enzymatic inhibition—specifically the β-lactamases that hydrolyze antibiotics before they reach their targets. In this continuation, the discussion turns to other major mechanisms of resistance, particularly among Gram-negative organisms.

The mechanisms covered here include:

1. Decreased permeability (porin loss or modification)

2. Promotion of antibiotic efflux (efflux pumps)

3. Altered target sites

4. Protection of target sites

5. Overproduction of target

As mentioned previously, the antibiogram can serve as a useful window into these molecular mechanisms. Patterns of susceptibility and resistance often reflect which of these processes is active within a given isolate. Because enzymatic inhibition plays a dominant role in Enterobacterales and other Gram-negative pathogens, it merited a separate post.

The remaining mechanisms discussed here together explain most of the additional resistance patterns encountered in Gram-negative bacteria. Gram-positive mechanisms—generally more straightforward—will be addressed in a subsequent installment.

Decreased Permeability: Porin Loss and Modification

Gram-negative bacteria possess an outer membrane composed of lipopolysaccharide (LPS), which functions as a permeability barrier. This LPS layer is hydrophobic and restricts the entry of many antibiotics. To permit access for hydrophilic nutrients and metabolites, these organisms express porins—protein channels that allow small, water-soluble molecules to diffuse through the outer membrane.

In Escherichia coli, for instance, the major porins OmpF and OmpC are differentially expressed depending on environmental osmolarity: OmpF predominates in low-osmolarity environments, while OmpC is upregulated under hyperosmolar conditions. The diffusion of antibiotics through these channels depends on the number and diameter of porins, as well as the physicochemical characteristics of the drug itself. In general, small, hydrophilic molecules such as imipenem diffuse readily, whereas large, hydrophobic, or negatively charged agents do not.

Mutations that reduce the number or function of porins markedly diminish permeability. The clinical result is resistance to multiple β-lactam classes—including third-generation cephalosporins (cefotaxime, ceftazidime), carbapenems (imipenem, meropenem), and even β-lactam/β-lactamase inhibitor combinations such as piperacillin-tazobactam or ceftolozane-tazobactam. The consequence is a phenotype of broad β-lactam resistance. However, porin loss also imposes a metabolic burden, as nutrient uptake becomes inefficient; bacteria with such mutations often grow more slowly, demonstrating the evolutionary trade-off between resistance and fitness.

Promotion of Antibiotic Efflux: The Efflux Pump Systems

Efflux pumps are membrane-associated proteins that actively export antimicrobial agents out of the bacterial cell, thereby reducing intracellular drug concentrations. This mechanism frequently acts synergistically with decreased permeability to confer multidrug resistance.

In E. coli, Shigella spp., and other Enterobacterales, efflux systems such as AcrAB-TolC and EmrAB can remove structurally diverse antibiotics. A classic example is tetracycline resistance, where the tet or otr genes encode proteins that pump tetracyclines out of the cell, leading to reduced drug accumulation.

Efflux also plays a major role in fluoroquinolone resistance. Plasmid-mediated systems such as qepA may confer selective resistance to one fluoroquinolone (e.g., ciprofloxacin) while leaving others (e.g., levofloxacin) active. Over time, additional resistance mechanisms—such as target site mutations or permeability alterations—may emerge, leading to class-wide resistance.

In Pseudomonas aeruginosa, efflux pumps are particularly important. The RND (resistance-nodulation-cell division) family of pumps exports fluoroquinolones, tetracyclines, aminoglycosides, and most β-lactams. These systems, acting in concert with β-lactamases and porin loss, explain the organism’s characteristic multidrug-resistant phenotype and the therapeutic challenges it presents.

Altered Target Sites

Another major category of resistance arises from modification of the antibiotic’s binding site. Such alterations reduce affinity for the drug while preserving the function of the target enzyme or structure.

• Aminoglycosides: Resistance can occur via methylation of the 16S rRNA at the aminoglycoside binding site, mediated by plasmid-encoded enzymes encoded by genes such as armA, rmtA–E, and npmA. This mechanism confers high-level resistance to virtually all aminoglycosides.

• Trimethoprim-sulfamethoxazole: Resistance is most commonly due to acquisition of sul1–3 or dfrA genes encoding drug-insensitive versions of dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR), respectively. These genes are often carried on mobile genetic elements, facilitating horizontal transfer.

• Fosfomycin: Mutations in the murA gene alter the target enzyme (UDP-N-acetylglucosamine enolpyruvyl transferase), decreasing drug binding.

• Fluoroquinolones: Mutations in the gyrA and parC genes—particularly within the quinolone resistance-determining region—alter DNA gyrase and topoisomerase IV binding sites, producing class-level resistance rather than drug-specific effects.

Protection of Target Sites

A distinct but related phenomenon involves protection rather than modification of the target. Plasmid-mediated qnr genes encode proteins that shield DNA gyrase from quinolone binding without altering the enzyme itself. This mechanism typically confers low-level resistance, but when combined with other mechanisms—such as gyrA mutations or efflux activity—it can raise resistance to clinically significant levels and contribute to therapeutic failure.

Overproduction of Target

Some bacteria resist antibiotics by overproducing the enzyme targeted by the drug, effectively overwhelming its inhibitory capacity. In the case of sulfonamides, overexpression of dihydropteroate synthase (DHPS), encoded by folP, can generate sufficient enzyme to maintain folate synthesis despite sulfonamide inhibition. Although less commonly discussed, this mechanism complements the acquisition of resistant enzyme variants in sustaining resistance.

Concluding Remarks

Together, these mechanisms complete the spectrum of clinically important resistance strategies among Gram-negative organisms. In clinical isolates, multiple mechanisms often coexist, yielding complex resistance phenotypes. Nonetheless, each antibiogram represents a functional portrait of these molecular interactions—a real-time manifestation of the evolutionary arms race between antimicrobial development and bacterial adaptation!

Stay tuned for Part III, where we’ll explore Gram-positive resistance mechanisms — from MRSA’s PBP2a to VRE’s altered D-Ala-D-Lac cell wall precursors.

Musical Coda